-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Anavex Life Sciences Analyst Ratings
Anavex Life Sciences Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 603.13% | HC Wainwright & Co. | → $54 | Reiterates | Buy → Buy |
| 07/20/2023 | — | HC Wainwright & Co. | Reiterates | Buy → Buy | |
| 06/29/2023 | 603.13% | HC Wainwright & Co. | → $54 | Reiterates | Buy → Buy |
| 05/02/2023 | 603.13% | HC Wainwright & Co. | → $54 | Reiterates | → Buy |
| 03/31/2023 | 603.13% | HC Wainwright & Co. | $50 → $54 | Maintains | Buy |
| 02/09/2023 | 264.58% | BTIG | $35 → $28 | Maintains | Buy |
| 02/09/2023 | 551.04% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 02/06/2023 | 551.04% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 01/03/2023 | 551.04% | HC Wainwright & Co. | $42 → $50 | Maintains | Buy |
| 12/06/2022 | 43.23% | Cantor Fitzgerald | $16 → $11 | Downgrades | Overweight → Neutral |
| 06/23/2022 | 420.83% | Berenberg | → $40 | Initiates Coverage On | → Buy |
| 02/02/2022 | 446.88% | HC Wainwright & Co. | $39 → $42 | Maintains | Buy |
| 09/23/2021 | 355.73% | BTIG | → $35 | Initiates Coverage On | → Buy |
| 06/28/2021 | 407.81% | HC Wainwright & Co. | $25 → $39 | Maintains | Buy |
| 06/15/2021 | 225.52% | HC Wainwright & Co. | $17 → $25 | Maintains | Buy |
| 02/23/2021 | 225.52% | Cantor Fitzgerald | $10 → $25 | Reiterates | → Overweight |
| 12/16/2020 | 121.35% | HC Wainwright & Co. | $14 → $17 | Maintains | Buy |
| 10/21/2020 | 82.29% | HC Wainwright & Co. | $12 → $14 | Maintains | Buy |
| 09/28/2020 | 56.25% | Ladenburg Thalmann | → $12 | Initiates Coverage On | → Buy |
| 03/16/2020 | 56.25% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 07/24/2019 | 108.33% | Dawson James | → $16 | Initiates Coverage On | → Buy |
| 06/18/2019 | 30.21% | Janney Montgomery Scott | → $10 | Initiates Coverage On | → Buy |
What is the target price for Anavex Life Sciences (AVXL)?
The latest price target for Anavex Life Sciences (NASDAQ: AVXL) was reported by HC Wainwright & Co. on August 8, 2023. The analyst firm set a price target for $54.00 expecting AVXL to rise to within 12 months (a possible 603.13% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Anavex Life Sciences (AVXL)?
The latest analyst rating for Anavex Life Sciences (NASDAQ: AVXL) was provided by HC Wainwright & Co., and Anavex Life Sciences reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Anavex Life Sciences (AVXL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anavex Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anavex Life Sciences was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
Is the Analyst Rating Anavex Life Sciences (AVXL) correct?
While ratings are subjective and will change, the latest Anavex Life Sciences (AVXL) rating was a reiterated with a price target of $0.00 to $54.00. The current price Anavex Life Sciences (AVXL) is trading at is $7.68, which is within the analyst's predicted range.
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 603.13% | HC Wainwright & Co. | → $54 | Reiterates | Buy → Buy |
| 07/20/2023 | — | HC Wainwright & Co. | Reiterates | Buy → Buy | |
| 06/29/2023 | 603.13% | HC Wainwright & Co. | → $54 | Reiterates | Buy → Buy |
| 05/02/2023 | 603.13% | HC Wainwright & Co. | → $54 | Reiterates | → Buy |
| 03/31/2023 | 603.13% | HC Wainwright & Co. | $50 → $54 | Maintains | Buy |
| 02/09/2023 | 264.58% | BTIG | $35 → $28 | Maintains | Buy |
| 02/09/2023 | 551.04% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 02/06/2023 | 551.04% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 01/03/2023 | 551.04% | HC Wainwright & Co. | $42 → $50 | Maintains | Buy |
| 12/06/2022 | 43.23% | Cantor Fitzgerald | $16 → $11 | Downgrades | Overweight → Neutral |
| 06/23/2022 | 420.83% | Berenberg | → $40 | Initiates Coverage On | → Buy |
| 02/02/2022 | 446.88% | HC Wainwright & Co. | $39 → $42 | Maintains | Buy |
| 09/23/2021 | 355.73% | BTIG | → $35 | Initiates Coverage On | → Buy |
| 06/28/2021 | 407.81% | HC Wainwright & Co. | $25 → $39 | Maintains | Buy |
| 06/15/2021 | 225.52% | HC Wainwright & Co. | $17 → $25 | Maintains | Buy |
| 02/23/2021 | 225.52% | Cantor Fitzgerald | $10 → $25 | Reiterates | → Overweight |
| 12/16/2020 | 121.35% | HC Wainwright & Co. | $14 → $17 | Maintains | Buy |
| 10/21/2020 | 82.29% | HC Wainwright & Co. | $12 → $14 | Maintains | Buy |
| 09/28/2020 | 56.25% | Ladenburg Thalmann | → $12 | Initiates Coverage On | → Buy |
| 03/16/2020 | 56.25% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 07/24/2019 | 108.33% | Dawson James | → $16 | Initiates Coverage On | → Buy |
| 06/18/2019 | 30.21% | Janney Montgomery Scott | → $10 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023/08/08 | 603.13% | HC Wainwright公司 | →$54 | 重申 | 购买→购买 |
| 07/20/2023 | - | HC Wainwright公司 | 重申 | 购买→购买 | |
| 2023年6月29日 | 603.13% | HC Wainwright公司 | →$54 | 重申 | 购买→购买 |
| 05/02/2023 | 603.13% | HC Wainwright公司 | →$54 | 重申 | →购买 |
| 03/31/2023 | 603.13% | HC Wainwright公司 | $50→$54 | 维护 | 买 |
| 02/09/2023 | 264.58% | BTIG | $35→$28 | 维护 | 买 |
| 02/09/2023 | 551.04% | HC Wainwright公司 | →$50 | 重申 | →购买 |
| 02/06/2023 | 551.04% | HC Wainwright公司 | →$50 | 重申 | →购买 |
| 01/03/2023 | 551.04% | HC Wainwright公司 | $42→$50 | 维护 | 买 |
| 12/06/2022 | 43.23% | 康托·菲茨杰拉德 | $16→$11 | 评级下调 | 超重→中性 |
| 2022/06/23 | 420.83% | 贝伦伯格 | →$40 | 开始承保 | →购买 |
| 02/02/2022 | 446.88% | HC Wainwright公司 | $39→$42 | 维护 | 买 |
| 09/23/2021 | 355.73% | BTIG | →$35 | 开始承保 | →购买 |
| 2021/06/28 | 407.81% | HC Wainwright公司 | $25→$39 | 维护 | 买 |
| 2021/06/15 | 225.52% | HC Wainwright公司 | $17→$25 | 维护 | 买 |
| 02/23/2021 | 225.52% | 康托·菲茨杰拉德 | $10→$25 | 重申 | →超重 |
| 12/16/2020 | 121.35% | HC Wainwright公司 | $14→$17 | 维护 | 买 |
| 10/21/2020 | 82.29% | HC Wainwright公司 | $12→$14 | 维护 | 买 |
| 09/28/2020 | 56.25% | 拉登堡·塔尔曼 | →$12 | 开始承保 | →购买 |
| 03/16/2020 | 56.25% | HC Wainwright公司 | →$12 | 开始承保 | →购买 |
| 2019年07月24日 | 108.33% | 道森·詹姆斯 | →$16 | 开始承保 | →购买 |
| 2019年06月18日 | 30.21% | 詹尼·蒙哥马利·斯科特 | →$10 | 开始承保 | →购买 |
What is the target price for Anavex Life Sciences (AVXL)?
Anavex Life Science(AVXL)的目标价是多少？
The latest price target for Anavex Life Sciences (NASDAQ: AVXL) was reported by HC Wainwright & Co. on August 8, 2023. The analyst firm set a price target for $54.00 expecting AVXL to rise to within 12 months (a possible 603.13% upside). 10 analyst firms have reported ratings in the last year.
阿纳维斯生命科学公司(纳斯达克：AVXL)的最新目标价是由HC Wainwright&Co.于2023年8月8日报道的。这家分析公司将目标价定为54美元，预计AVXL将在12个月内上涨至(可能上涨603.13%)。去年有10家分析公司公布了评级。
What is the most recent analyst rating for Anavex Life Sciences (AVXL)?
Anavex Life Science(AVXL)的最新分析师评级是多少？
The latest analyst rating for Anavex Life Sciences (NASDAQ: AVXL) was provided by HC Wainwright & Co., and Anavex Life Sciences reiterated their buy rating.
分析师对Anavex生命科学公司(纳斯达克代码：AVXL)的最新评级由HC Wainwright&Co.提供，Anavex生命科学公司重申其买入评级。
When is the next analyst rating going to be posted or updated for Anavex Life Sciences (AVXL)?
Anavex Life Science(AVXL)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anavex Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anavex Life Sciences was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Anavex生命科学的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Anavex生命科学的上一次评级是在2023年8月8日提交的，因此您应该预计下一次评级将在2024年8月8日左右提供。
Is the Analyst Rating Anavex Life Sciences (AVXL) correct?
分析师对Anavex Life Science(AVXL)的评级正确吗？
While ratings are subjective and will change, the latest Anavex Life Sciences (AVXL) rating was a reiterated with a price target of $0.00 to $54.00. The current price Anavex Life Sciences (AVXL) is trading at is $7.68, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Anavex生命科学(AVXL)评级被重申，目标价在0.00美元至54.00美元之间。Anavex Life Science(AVXL)目前的交易价格为7.68美元，在分析师的预测范围内。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧